Medicine and Dentistry
Status Epilepticus
100%
Disease Course
100%
COVID-19
100%
Epileptic Seizure
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Infection
68%
Blood Donor
54%
Finger Dermatoglyphics
50%
Reinfection
50%
Head and Neck Cancer
50%
Alveolar Ridge
50%
Quality of Life
50%
Case-Control Study
50%
Magnetic Resonance Imaging
50%
Life Expectancy
50%
Stereoelectroencephalography
50%
Post-COVID-19
50%
Physical Activity
50%
Exercise
50%
Heart Rehabilitation
50%
Virus Reactivation
50%
Epstein Barr Virus
50%
Population
37%
Patient with Epilepsy
33%
Prosthetics
33%
Partial Seizure
30%
Jaw
25%
Pulvinar
22%
Thalamus
22%
Diagnosis
20%
Epilepsy Surgery
20%
Hippocampus
18%
Case Fatality Rate
16%
Prematurity
16%
Epilepsy Syndromes
16%
Middle Age
16%
Short Form 36
16%
Prosthesis
16%
Physical Medicine and Rehabilitation
16%
Prospective Study
10%
Drug Resistant Epilepsy
10%
Clinician
10%
Diagnostic Accuracy
10%
Antiviral Immune Response
9%
Neopterin
9%
Immunoassay
9%
Virus DNA
9%
Public Health Policy
8%
Primary Infection
8%
Accelerometry
8%
Mathematics
Count Data
57%
Crossover
50%
Binary Data
50%
Population
50%
Pairwise Comparison
50%
Ordinal Data
50%
Finite Population
50%
Wald
50%
High Power
50%
Outcome Variable
50%
time point η
50%
Marginal Model
50%
Simplex
50%
Type Statistic
50%
Matrix (Mathematics)
50%
Projection Matrix
37%
Optimal Design
28%
Interaction Effect
25%
Statistical Method
25%
Parametric Model
25%
Crossover Design
25%
Estimating Equation
25%
Quadratic Form
25%
Treatment Effect
21%
Fisher Information Matrix
14%
Information Gain
14%
Upper Triangular
12%
Parameter Vector
12%
Test Statistic
12%
Regression Coefficient
12%
Covariance Matrix
12%
Dimensional Data
12%
Quantile
12%
Assumed Model
7%
Time Increase
7%
Concludes
7%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
100%
Disease Course
100%
Infection
68%
Syndrome
66%
Epileptic State
50%
Life Expectancy
50%
Clinical Trial
50%
Epidermolysis Bullosa Simplex
50%
Reinfection
50%
Genodermatosis
50%
Premature Mortality
50%
Randomized Controlled Trial
50%
Deterioration
50%
Heart Disease
50%
Epstein-Barr Virus
50%
Blister
21%
Case Fatality Rate
16%
Prematurity
16%
Normal Human
12%
Disease
11%
Virus DNA
9%
Neopterin
9%
Antivirus Agent
9%
Immunoassay
9%
Public Health Policy
8%
Primary Infection
8%
Skin Disease
7%
Rare Disease
7%
